U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday.

Shares of Esperion Therapeutics, Inc. ESPR rose sharply in today’s pre-market trading.

The U.S. FDA approved broad new labels for Esperion's NEXLETOL® and NEXLIZET® to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.

Esperion Therapeutics shares jumped 12.7% to $2.58 in pre-market trading.

Here are some big stocks recording gains in today’s pre-market trading session.

  • Forge Global Holdings, Inc. FRGE shares gained 22.8% to $2.86 in pre-market trading after gaining 13% on Friday.
  • Canopy Growth Corporation CGC gained 19.5% to $9.17 in pre-market trading. The German government approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.
  • Masimo Corporation MASI shares climbed 13.8% to $153.65 in pre-market trading after the company announced it has authorized management to evaluate a proposed separation of its consumer business. The company also reaffirmed its first-quarter and FY24 guidance.
  • Cronos Group Inc. CRON rose 9.6% to $2.86 in pre-market trading after gaining 9% on Friday.
  • Nuvation Bio Inc. NUVB gained 8.2% to $2.50 in pre-market trading after gaining 3% on Friday.
  • Tilray Brands, Inc. TLRY gained 5.2% to $2.43 in pre-market trading after jumping 18% on Friday. Germany approved the legalization of cannabis for adult use.
  • WK Kellogg Co KLG rose 4.8% to $19.49 in pre-market trading.
  • GoodRx Holdings, Inc. GDRX shares climbed 4.1% to $6.85 in pre-market trading. Wells Fargo analyst Stan Berenshteyn upgraded GoodRx from Equal-Weight to Overweight and announced a $10 price target.
  • Century Aluminum Company CENX shares gained 3.6% to $13.69 in pre-market trading.

 

Now Read This: Investor Optimism Improves Slightly; Dow Jumps Over 250 Points

Don’t forget to check out our premarket coverage here

Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!